Hemostemix Inc. (TSX-V: HEM, OTC: HMTXF, Forum) released the results of its Annual Special Meeting of Shareholders this
week, where a motion to consolidate common shares on a one new share for each 20 shares issued basis was approved.
For more on these results, click
here.
The publicly traded autologous stem cell therapy Company recently appointed
David H. Tsubouchi to its Board of Advisors. The first Japanese Canadian to be elected to any provincial legislature in Canada and to be appointed as a Cabinet Minister, he had served as the Minister of Consumer and Commercial Relations, Solicitor General, Chair of Management Board and Minister of Culture.
The Company developed and is commercializing its lead product ACP-01 for the treatment of critical limb ischemia (CLI), Peripheral artery disease (PAD), Angina, Ischemic Cardiomyopathy, Dilated Cardiomyopathy and other conditions of ischemia.
FULL DISCLOSURE: Hemostemix Inc. is a client of Stockhouse Publishing.